RT Journal Article
SR Electronic
T1 The proportion of Alzheimer’s disease attributable to apolipoprotein E
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.16.23298475
DO 10.1101/2023.11.16.23298475
A1 Williams, Dylan M.
A1 Davies, Neil M.
A1 Anderson, Emma L.
YR 2024
UL http://medrxiv.org/content/early/2024/03/07/2023.11.16.23298475.abstract
AB The extent to which genetic variation at the APOE locus explains the burden of late-onset Alzheimer’s disease (AD) is poorly understood. We provide new estimates of the proportions of AD and all-cause dementia attributable to carriage of ε3 and/or ε4 alleles of APOE, using data from 171,133 participants of the UK Biobank cohort study. AD and all-cause dementia were ascertained at baseline and during follow-up via linked electronic health records for up to 16.8 years. We estimate that 74.5% (95% CI: 38.6, 89.4) of AD and 39.5% (95% CI: 10.7, 59.1%) of all-cause dementia burden is attributable to ε3 and ε4 carriage. Thus, differences in the molecular physiology of apolipoprotein E cause most AD and a large fraction of all dementia. Research into this pathway should be prioritised to facilitate dementia prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe MRC Unit for Lifelong Health and Ageing at UCL is funded by the Medical Research Council (MC_UU_00019/3). NMD is supported via a Norwegian Research Council Grant number 295989. ELA is supported by a UKRI Future Leaders Fellowship (MR/W011581/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:North West Haydock Research Ethics Committee of the UK Health Research Authority gave ethical approval for the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data used in this research are available to researchers that register with UK Biobank and request access to them as part of an approved project. https://www.ukbiobank.ac.uk/